Clinical trials: Liver Cancer (Primary and Metastatic)
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase
TKM 080301 for Primary or Secondary Liver Cancer
Background: Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g.
- Conditions
- Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase, Gastric Cancer With Hepatic Metastase, Breast Cancer With Hepatic Metastase
- Trial name
- NCT01437007
- Testing
- TKM-080301
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Trial of TG4023 Combined With Flucytosine in Liver Tumors
This trial is a phase I, open-label, dose-escalating study of the safety or percutaneous intra-tumoral injection of TG4023 (MVA-FCU1) combined with systemic administration of 5-fluorocytosine in patients with primary or secondary…
- Trial name
- NCT00978107
- Testing
- MVA-FCU1, flucytosine
- Where
- 6 sites in France
- Volunteers
- 16 people
- Sponsor
- Transgene
Liver Cancer
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00128596
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pain
- Trial name
- NCT00073905
- Testing
- capecitabine plus gemcitabine
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Swiss Cancer Institute
Cancer
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Indinavir and ritonavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00637637
- Testing
- indinavir sulfate, ritonavir, radiation therapy
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Liver Cancer, Metastatic Cancer
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as yttrium Y 90 glass microspheres that deliver a high dose of radiation directly to the…
- Trial name
- NCT00858429
- Testing
- capecitabine, yttrium Y 90 glass microspheres
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Northwestern University
Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC)
Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma
The goal of this observational study is to evaluate how well first-line immunotherapy works and investigate its association with immune-related adverse events (irAEs) in Egyptian adults with unresectable hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable, Hepatocellular Carcinoma Metastatic
- Trial name
- NCT07904494
- Testing
- Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab
- Where
- 4 sites in Egypt
- Volunteers
- 294 people
- Sponsor
- Assiut University
Breast Carcinoma, Carcinoma of Unknown Primary
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver…
- Conditions
- Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma
- Trial name
- NCT01366144
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
This phase II trial is to see if bevacizumab works in treating patients who have unresectable nonmetastatic liver cancer that has not spread to the main portal vein.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00055692
- Testing
- bevacizumab
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This phase II trial is studying selumetinib to see how well it works in treating patients with locally advanced or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00604721
- Testing
- selumetinib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Neoplasms, Hepatocellular Cancer
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
The purpose of the study is to evaluate whether the novel anti-cancer drug OXY111A is safe and tolerated in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the…
- Conditions
- Pancreatic Neoplasms, Hepatocellular Cancer, Cholangiocarcinoma, Colorectal Neoplasms
- Trial name
- OXY1A (NCT02528526)
- Testing
- OXY111A
- Where
- Switzerland
- Volunteers
- 69 people
- Sponsor
- University of Zurich
Neoplasms
A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection
5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD.
- Trial name
- NCT00264446
- Testing
- ADH300004
- Where
- United States
- Sponsor
- Adherex Technologies, Inc.
Liver Cancer, Liver Neoplasms
Therasphere for Unresectable Primary or Secondary Liver Neoplasia
This is not a research study. The purpose is to provide supervised access to TheraSphere® therapy at this institution.
- Conditions
- Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma
- Trial name
- NCT02960620
- Testing
- TheraSphere Treatment
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal…
- Trial name
- NCT02842125
- Testing
- Ad-P53, Xeloda, Keytruda
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- MultiVir, Inc.
Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
This phase I trial is studying the side effects and best dose of vorinostat in treating patients with metastatic or unresectable solid tumors or lymphoma and liver dysfunction.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00499811
- Testing
- vorinostat, pharmacological study
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Liver Tumour
Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours
This proof of concept study proposes targeted delivery of a broad-spectrum cytotoxic agent (doxorubicin), via a specially formulated LTSL (ThermoDox®) activated by mild hyperthermia, by using focused ultrasound (FUS), to achieve…
- Trial name
- TARDOX (NCT02181075)
- Testing
- ThermoDox® (LTLD), Focused Ultrasound of Target Liver Tumour, Pre-LTLD Biopsy of Target Liver Tumour
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Oxford
Liver Cancer, Hepatic Tumors
Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors
This is a prospective non-blinded case series involving the acquisition of a pair production PET/CT as soon as possible after an already performed Y-90 Sirspheres treatment of hepatic malignancy.
- Trial name
- NCT02202317
- Testing
- PET/CT Scan
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Miami
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Liver Tumors
Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS)
One of the limiting factors in the execution of a liver resection, in particular an extended liver resection, it's represented by the future remnant liver (FRL) after hepatic surgery.
- Trial name
- LAPS (NCT02184182)
- Testing
- VLS ablation/portal ligation/hepatectomy
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Azienda Ospedaliera di Padova